MedTrace Logo

Peptide Receptor Radionuclide Therapy Administered to Participants With Meningioma With 67Cu-SARTATE™

NCT03936426 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2020-04-20

No results posted yet for this study

Summary

The primary purpose of this study is to investigate the safety and tolerability of a single dose of Cu-64 SARTATE and multiple doses of Cu-67 SARTATE administered to participants with meningioma. All participants in this study will be injected with a single dose of Cu-64 SARTATE to demonstrate how it is absorbed in the body. Then participants will receive individualised doses of Cu-67 SARTATE for up to 4 cycles.

Conditions

  • Meningioma

Interventions

DRUG

Cu-64 SARTATE and Cu-67 SARTATE

Cu-64 SARTATE diagnostic drug Cu-67 SARTATE therapy drug

Sponsors & Collaborators

  • Clarity Pharmaceuticals Ltd

    lead INDUSTRY

Principal Investigators

  • Geoffrey Schembri, MD · Royal North Shore Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-09
Primary Completion
2019-09-19
Completion
2019-09-19

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03936426 on ClinicalTrials.gov